China's ZBD to Sell Indian Biological E.'s Superbug Drug in China - (Yicai Global via NewsPoints Desk)

  • ZBD Pharmaceutical will pay $100,000 to India's Biological E. to gain the exclusive right to sell daptomycin, an intravenous antibiotic used to treat complicated infections such as methicillin-resistant Staphylococcus aureus, in China, reported Yicai Global.

  • ZBD will be in charge of trying to get the drug approved in China, the company stated.

  • In 2018, the Chinese market for the drug, which was originally launched by Eli Lilly in the US, doubled from a year earlier to CNY60 million, with Hengrui Medicine producing more than half of the sold product, the company added.

To read more NewsPoints articles, click here.